ARCHIMED Acquires Majority Stake in Arkstone

July 31, 2025
Arkstone, a biotechnology company specializing in AI-driven clinical decision support, has been acquired by ARCHIMED, a healthcare-focused private equity firm, as announced in a press release.

ARCHIMED has acquired a majority stake in Arkstone Medical Solutions, a biotechnology company known for its AI-driven clinical decision support systems. This acquisition, announced in a press release, aims to enhance Arkstone's global reach and accelerate its research and development capabilities.

Arkstone's flagship product, the OneChoice Report, utilizes machine learning and AI to provide precise infectious disease treatment recommendations by analyzing laboratory results and patient data. This tool is already in use across various laboratories in the United States and internationally, transforming how healthcare providers diagnose and treat infectious diseases.

With ARCHIMED's investment and expertise, Arkstone plans to expand its market presence and further develop its products to combat antimicrobial resistance, a significant public health challenge. The acquisition will allow Arkstone to continue operating with its existing team while focusing on rapid growth and innovation.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

AI Funding News Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Funding

09/04
Guardio Raises $40 Million at $1.1 Billion Valuation
09/03
Flex to Acquire EPC Power for $4.4 Billion
09/03
NVIDIA Agrees to Acquire Hugging Face for $12.93 Billion
09/03
Superluminal Medicines Raises $60 Million for Obesity Drug Trial
09/02
MulticoreWare Acquires Simulus Automation for Semiconductor Design

More from: Life Sciences

09/04
ODYSS Unveils N1 AI Necklace for Food Logging
09/04
Withings Adds AI Heart and Lung Sound Analysis to BeamO
09/03
CluePoints Releases Three AI Tools for Clinical Data Review
09/03
Authenticx Adds Form Automation and Routing to Safety AI
09/03
Superluminal Medicines Raises $60 Million for Obesity Drug Trial

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like